[Skip to Content]
[Skip to Content Landing]
Citations 0
Letters
February 10, 2010

Association Between CYP2D6 Polymorphisms and Breast Cancer Outcomes

JAMA. 2010;303(6):516-517. doi:10.1001/jama.2010.93

To the Editor: Dr Schroth and colleagues1 described differences in efficacy of adjuvant tamoxifen on breast cancer outcome by an individual's CYP2D6 status. This 2-cohort study (609 extensive metabolizers and 716 decreased metabolizers) included prospectively collected data from 212 patients (enrolled 1991-1995)2 and retrospectively collected data from 1113 German patients (apparently 138 diagnosed before 20003 and 975 diagnosed after 2000).

×